Leerink Partners Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $38

Benzinga Newsdesk www.benzinga.com Positive 79.3%

Neg 0% Neu 0% Pos 79.3%

Leerink Partners analyst Thomas Smith initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Outperform rating and announces Price Target of $38.